One in 5 parents of boys said the main reason that they haven’t vaccinated their sons for HPV was because they didn’t receive a recommendation for the vaccination, compared with 1 in 10 girls, said Anna Beavis, MD, MPH, a gynecologic oncologist fellow at Johns Hopkins University.
One in 5 parents of boys said the main reason that they haven’t vaccinated their sons for HPV was because they didn’t receive a recommendation for the vaccination, compared with 1 in 10 girls, said Anna Beavis, MD, MPH, a gynecologic oncologist fellow at Johns Hopkins University.
Transcript
What gender differences have you identified in HPV vaccination?
We did the study because we know boys are less likely to get vaccinated with the HPV vaccination compared to girls in the United States, although both are actually lagging behind the recommended vaccination rates in other westernized nations and the goal for the United States. Mainly we saw that for both, lack of necessity was a common reason as well as lack of knowledge about the vaccine.
Broken down by gender, where we saw the big differences, where that parents of boys much more commonly reported that lack of recommendation from a physician was the biggest driver. One in 5 parents of boys says the main reason that they haven’t vaccinated was because they didn’t receive a recommendation for the vaccination, compared to 1 in 10 girls. We also saw that parents of girls were more likely to report concerns about safety and side effects and a concern that their child wasn’t sexually active yet as their main reason for lack of vaccination compared to boys.
What interventions are needed to close this gap between genders?
I think the biggest intervention that providers — and that includes nurses, advanced practitioners, such as physician assistants and nurse practitioners, as well as physicians – can really do is provide a strong, clear recommendation that the vaccine provides cancer prevention, and it’s not just for girls, it’s also for boys. It is effective against cancers that affect both genders as well as cancers that specifically affect girls and women.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS
June 2nd 2025Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.
Read More
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More